Investors focused on the Medical space have likely heard of Editas Medicine (EDIT - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Editas Medicine is a member of the Medical sector. This group includes 763 individual stocks and currently holds a Zacks Sector Rank of #11. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. EDIT is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for EDIT's full-year earnings has moved 0.33% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, EDIT has moved about 23.43% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 0.38% on average. This means that Editas Medicine is performing better than its sector in terms of year-to-date returns.
Looking more specifically, EDIT belongs to the Medical - Biomedical and Genetics industry, which includes 282 individual stocks and currently sits at #165 in the Zacks Industry Rank. This group has lost an average of 5.49% so far this year, so EDIT is performing better in this area.
Going forward, investors interested in Medical stocks should continue to pay close attention to EDIT as it looks to continue its solid performance.